|
Domus Bibliotheca - Auditorium 14
|
|||
|
12:00 pm |
Ultan McDermott
|
Using functional genomics for novel target identification in oncology |
|
|
01:00 pm |
Yngvar Fløisand
|
Vedolizumab for Prophylaxis of Lower GI aGVHD After allo-HSCT From Unrelated Donors: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study (GRAPHITE)
|
|
|
Oslo Bar & Bowling
|
|||
|
02:00 – 04:00 pm |
Pizza & Bowling with CanCell members
|
||
Ultan McDermott
Ultan McDermott is Chief Scientist in Oncology at AstraZeneca and a clinician scientist. He has a lifelong interest in understanding how cancer genomes affect response in the clinic to therapy, and more recently the use of CRISPR screens and single cell sequencing to identify novel targets for cancer treatment.
Ultan joined the Wellcome Sanger Institute in 2009 as a Group Leader and member of Faculty. Previously he worked as a postdoctoral fellow with Jeff Settleman at Massachusetts General Hospital Cancer Center on high-throughput cancer cell line drug screens and resistance mechanisms. In 2018 he joined AstraZeneca as Chief Scientist in Oncology.
He is a Fellow of the Royal College of Physicians and continues to practice as an oncologist at Cambridge University Hospitals NHS Foundation Trust.
Yngvar Fløisand
Dr Floisand MD PhD, graduated from Heinrich Heine University in Düsseldorf in 1995 and trained Internal Medicine and Hematology in Oslo, Norway.
He was Clinical and Research Lead for AML at Oslo University Hospital from 2012 – 2020 and has special interest in AML and acute graft-versus-host disease after allogeneic stem cell transplantation
He has been PI of numerous clinical trial and a member of several international collaborative groups.
From 2020 – 2022, he was Clinical Research Lead and Ass. Director of Stem Cell Transplantation and Celllular Therapy at Clatterbridge Cancer Centre, Liverpool, UK.
Currently, he is self-employed Hematologist and Consultant based in Oslo, Norway.
He is author and co-author of more than 75 publications in peer reviewed journals.